AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6225396 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 3
Study 31662866 — intervention group
Group type: EXPERIMENTAL
Intervention: XG + PPT + XOS
Number of subjects: 60
Study 31662866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29920532 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 10
Study 29920532 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 10
Study 26684150 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1‐84) 50 μg/day, escalated to 75 and then to 100 μg/day if needed
Number of subjects: 24
Study 26684150 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1‐84)
Number of subjects: 24
Study 24162168 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal drainage tube (TDT)
Number of subjects: 29
Study 24162168 — intervention group
Group type: COMPARATOR
Intervention: Metallic stent
Number of subjects: 29
Study 22154609 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ED‐saving strategy including prospective ECG triggering with a short x‐ray window and a BMI‐adapted imaging protocol using adaptive statistical iterative reconstruction (ASIR)
Number of subjects: 156
Study 22154609 — intervention group
Group type: COMPARATOR
Intervention: Prospective ECG triggering strategy alone
Number of subjects: 156
Study 19160156 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar forceps via TGA
Number of subjects: 12
Study 19160156 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar forceps via TVA
Number of subjects: 12
Study 19160156 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced argon plasma coagulation (FAPC) via TGA
Number of subjects: 12
Study 19160156 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced argon plasma coagulation (FAPC) via TVA
Number of subjects: 12
Study 19160156 — intervention group
Group type: EXPERIMENTAL
Intervention: FAPC for additional treatment of bleeding from the main gastroepiploic artery via TGA
Number of subjects: 12
Study 19160156 — intervention group
Group type: EXPERIMENTAL
Intervention: FAPC for additional treatment of bleeding from the main gastroepiploic artery via TVA
Number of subjects: 12
Study 17394035 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin
Number of subjects: 64
Study 17394035 — intervention group
Group type: EXPERIMENTAL
Intervention: alfuzosin
Number of subjects: 64
Study 15723023 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MDD and concurrent SUD symptoms
Number of subjects: 1484
Study 15723023 — intervention group
Group type: COMPARATOR
Intervention: Patients without concurrent SUD symptoms
Number of subjects: 1484
Study 12572379 — intervention group
Group type: EXPERIMENTAL
Intervention: Jietongyin Lotion (JTYL)
Number of subjects: 360
Study 12572379 — intervention group
Group type: COMPARATOR
Intervention: Rishu an Lotion (Control)
Number of subjects: 360
Study 9467475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 81
Study 9467475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg twice daily
Number of subjects: 81
Study 9467475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine dosages of ≤ 2 mg
Number of subjects: 81
Study 9467475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 7637351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 316
Study 7637351 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion
Number of subjects: 316
Study 1978372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone at 7.5 mg t.i.d. for 4 weeks
Number of subjects: 34
Study 1978372 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 34
Study 1978372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone
Number of subjects: 34
Study 1978372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 356239 — intervention group
Group type: EXPERIMENTAL
Intervention: Proquazone (900 mg)
Number of subjects: 44
Study 356239 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (1200 mg)
Number of subjects: 44
Study 31722332 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone dialysis membrane
Number of subjects: 25
Study 31722332 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA dialysis membrane
Number of subjects: 25
Study 31194916 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced retrieval using dynamic images (video clips without audio)
Number of subjects: 12
Study 31194916 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced retrieval using static images
Number of subjects: 12
Study 31194916 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced retrieval using dynamic images
Number of subjects: 12
Study 27481207 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (CTLA4-Ig) administered via monthly intravenous infusions for 24 weeks, switched to placebo at 28 weeks, final dose at 52 weeks.
Number of subjects: 65
Study 27481207 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered via monthly intravenous infusions for 24 weeks, switched to abatacept at 28 weeks, final dose at 52 weeks.
Number of subjects: 65
Study 25841032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 0
Study 25841032 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dihydroergotamine (DHE)
Number of subjects: 0
Study 23630134 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy brain ageing cognitive training program (psychoeducation and cognitive training)
Number of subjects: 50
Study 21635791 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRA Dhanusha community groups
Number of subjects: 270
Study 21635791 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRA Dhanusha sepsis management
Number of subjects: 270
Study 19147478 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up by specialist nurses
Number of subjects: 374
Study 19147478 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospital follow-up
Number of subjects: 374
Study 19147478 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 374
Study 16855921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (1/4 - 1 mg/day)
Number of subjects: 30
Study 16855921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 30
Study 12865603 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) pretreatment
Number of subjects: 300
Study 12865603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 300
Study 12865603 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose heparin
Number of subjects: 300
Study 12865603 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke severity (NIHSS) at baseline
Number of subjects: 300
Study 10885439 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA irradiation (70% of the individual's predetermined minimal phototoxic dose)
Number of subjects: 8
Study 10885439 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiation control session
Number of subjects: 8
Study 8967586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%, 3 ml (15 mg)
Number of subjects: 40
Study 8967586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%, 3 ml (22.5 mg)
Number of subjects: 40
Study 8967586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 40
Study 8967586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 40
Study 8967586 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 1457358 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (20 mg d-1)
Number of subjects: 114
Study 1457358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 6746977 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vivo participant modeling
Number of subjects: 26
Study 6746977 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal participant modeling
Number of subjects: 26
Study 31490271 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sutureless and glue-free method (group 1)
Number of subjects: 73
Study 31490271 — intervention group
Group type: COMPARATOR
Intervention: Conventional sutures (group 2)
Number of subjects: 73
Study 30266608 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified medical therapy (intervention group)
Number of subjects: 151
Study 30266608 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 151
Study 26995777 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal mobilisation with movement (MWM)
Number of subjects: 22
Study 26995777 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal self-mobilisation with movement (SMWM)
Number of subjects: 22
Study 26995777 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 24264126 — intervention group
Group type: EXPERIMENTAL
Intervention: TmLRP‐TT
Number of subjects: 90
Study 24264126 — intervention group
Group type: COMPARATOR
Intervention: PKRP
Number of subjects: 90
Study 22363761 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to personal health records (PHR) or general health information portals
Number of subjects: 338
Study 22363761 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to access and navigate individualized online accounts and complete study surveys
Number of subjects: 338
Study 22363761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive on-study training
Number of subjects: 338
Study 20660670 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (CAS) 50 mg/day; day 1, 70 mg
Number of subjects: 55
Study 20660670 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (LAMB) 3 mg/kg of body weight/day
Number of subjects: 55
Study 20660670 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CAS and LAMB (CASLAMB)
Number of subjects: 55
Study 20660670 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin (CAS)
Number of subjects: 55
Study 20660670 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (LAMB)
Number of subjects: 55
Study 17437745 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased pulmonary pressure
Number of subjects: 388
Study 17437745 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular systolic pressure increase
Number of subjects: 388
Study 16363196 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg plus 2 g/day chitosan in two divided doses
Number of subjects: 100
Study 16363196 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg plus placebo
Number of subjects: 100
Study 11984689 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 106
Study 11984689 — intervention group
Group type: COMPARATOR
Intervention: Open Nissen fundoplication
Number of subjects: 106
Study 11528488 — intervention group
Group type: EXPERIMENTAL
Intervention: HPOHC diet (high in palm oil and high in eggs)
Number of subjects: 28
Study 11528488 — intervention group
Group type: EXPERIMENTAL
Intervention: LOPOMC diet (no palm oil and moderate in eggs)
Number of subjects: 28
Study 9389862 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate in propylene glycol
Number of subjects: 49
Study 9389862 — intervention group
Group type: COMPARATOR
Intervention: Etomidate in lipid emulsion
Number of subjects: 49
Study 7956214 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptive (9-week on, 1-week off regimen)
Number of subjects: 30
Study 7956214 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel-containing oral contraceptive (traditional regimen)
Number of subjects: 30
Study 7956214 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptive (both regimens)
Number of subjects: 30
Study 3575253 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline-sodium-glycinate solution administered orally after a standard breakfast (5.6 mg/kg body weight)
Number of subjects: 10
Study 3575253 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline-sodium-glycinate solution administered orally on an empty stomach (5.6 mg/kg body weight)
Number of subjects: 10
Study 3575253 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of theophylline-sodium-glycinate solution under fasting conditions
Number of subjects: 10
Study 3575253 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of theophylline-sodium-glycinate solution
Number of subjects: 10
Study 28749093 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume saphenous‐obturator block
Number of subjects: 82
Study 28749093 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral‐obturator block
Number of subjects: 82
Study 28749093 — intervention group
Group type: COMPARATOR
Intervention: Placebo block
Number of subjects: 82
Study 27584814 — intervention group
Group type: EXPERIMENTAL
Intervention: HF10 therapy
Number of subjects: 198
Study 27584814 — intervention group
Group type: COMPARATOR
Intervention: Traditional SCS
Number of subjects: 198
Study 26568428 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4 then 200 mg every 2 weeks (Q2W)
Number of subjects: 955
Study 26568428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Q2W) during the double-blind phase, then switched to CZP in the open-label phase
Number of subjects: 955
Study 26568428 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 955
Study 24015649 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced percutaneous vertebroplasty
Number of subjects: 28
Study 24015649 — intervention group
Group type: COMPARATOR
Intervention: Routine percutaneous vertebroplasty
Number of subjects: 28
Study 20799592 — intervention group
Group type: EXPERIMENTAL
Intervention: silymarin (70 mg x 3/day)
Number of subjects: 40
Study 20799592 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 19057252 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac arthrodesis using percutaneously inserted fusion cages filled with bone morphogenic protein
Number of subjects: 13
Study 19057252 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 13
Study 16806096 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (titrated to a maximum dose of 1.8 mg/kg/day) administered once daily for up to 7 weeks
Number of subjects: 318
Study 16806096 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 318
Study 12782954 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of metronidazole by mouth in addition to standard care (240 mg gentamicin IM and 100 mg doxycycline twice daily for 7 days)
Number of subjects: 411
Study 12782954 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to standard care (240 mg gentamicin IM and 100 mg doxycycline twice daily for 7 days)
Number of subjects: 411
Study 12782954 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of metronidazole
Number of subjects: 411
Study 12782954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 12782954 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of HIV-infected men with trichomoniasis
Number of subjects: 411
Study 12782954 — intervention group
Group type: COMPARATOR
Intervention: HIV-positive control subjects
Number of subjects: 411
Study 10971246 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (Group 2)
Number of subjects: 80
Study 10971246 — intervention group
Group type: COMPARATOR
Intervention: Noncoated circuits (Group 1)
Number of subjects: 80
Study 8780763 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed local anesthetic solution at 40 degrees C
Number of subjects: 16
Study 8780763 — intervention group
Group type: COMPARATOR
Intervention: Room temperature local anesthetic solution
Number of subjects: 16
Study 1610995 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated arterial blood pressure during CPB (Group 1, 14 patients)
Number of subjects: 21
Study 1610995 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine to maintain arterial pressure above 70 mmHg (Group 2, 7 patients)
Number of subjects: 21
Study 1610995 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 29970144 — intervention group
Group type: EXPERIMENTAL
Intervention: noisy galvanic vestibular stimulation (nGVS) (0.4 mA; 0.1-640 Hz)
Number of subjects: 32
Study 29970144 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation (control)
Number of subjects: 32
Study 26890554 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded lullabies
Number of subjects: 62
Study 26890554 — intervention group
Group type: EXPERIMENTAL
Intervention: Taped maternal voice
Number of subjects: 62
Study 26890554 — intervention group
Group type: COMPARATOR
Intervention: No standardized acoustic stimulation (control group)
Number of subjects: 62
Study 24007426 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 130
Study 24007426 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 130
Study 22569131 — intervention group
Group type: EXPERIMENTAL
Intervention: Home performance on heating soup
Number of subjects: 33
Study 22569131 — intervention group
Group type: EXPERIMENTAL
Intervention: Home performance on cutting fruit
Number of subjects: 33
Study 19710251 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily inhaled corticosteroid (ICS) medication adherence
Number of subjects: 92
Study 18430852 — intervention group
Group type: EXPERIMENTAL
Intervention: (1)H-MR spectroscopy
Number of subjects: 39
Study 16870741 — intervention group
Group type: EXPERIMENTAL
Intervention: High-field functional magnetic resonance imaging and wide-field retinotopic stimulation
Number of subjects: 34
Study 16870741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical surface-based analysis
Number of subjects: 34
Study 12563673 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha monoclonal antibody
Number of subjects: 29
Study 12563673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11289667 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme linked immuno assay (ELISA) for detection of 170 kDa lectin antigen in feces
Number of subjects: 170
Study 11289667 — intervention group
Group type: COMPARATOR
Intervention: Fecal culture method
Number of subjects: 170
Study 11289667 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of fecal anti‐lectin IgA antibodies and serum anti‐LC3 IgG antibodies
Number of subjects: 170
Study 11289667 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection with Trichomonas hominis
Number of subjects: 170
Study 11289667 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection with Blastocystis hominis
Number of subjects: 170
Study 9069480 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient with cerebellar lesion
Number of subjects: 1
Study 9069480 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 1
Study 8422345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil ethyl ester (K‐85, 5.7 g/day)
Number of subjects: 14
Study 8422345 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/day)
Number of subjects: 14
Study 8422345 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of K‐85 and Lovastatin
Number of subjects: 14
Study 8422345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as control)
Number of subjects: 14
Study 3722962 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (RMP) 900 mg once weekly for ten weeks
Number of subjects: 0
Study 3722962 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C: daily RMP 600 mg, ethionamide (ETH) 500 mg, and DDS or clofazimine (CLO) 100 mg for six months, followed by six months of daily DDS or CLO
Number of subjects: 0
Study 3722962 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen D: identical to regimen C but comprising daily DDS or CLO plus ETH 500 mg during the second semester
Number of subjects: 0
Study 3722962 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine (CLO) 100 mg daily
Number of subjects: 0
Study 3722962 — intervention group
Group type: COMPARATOR
Intervention: MB-WHO regimen
Number of subjects: 0
Study 3722962 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens C and D
Number of subjects: 0
Study 29439005 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised mobile app intervention for three months
Number of subjects: 0
Study 29439005 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26889794 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (n=9)
Number of subjects: 15
Study 26889794 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (n=6)
Number of subjects: 15
Study 26889794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Active tDCS and Sham tDCS)
Number of subjects: 15
Study 24269507 — intervention group
Group type: EXPERIMENTAL
Intervention: New DIETs (plant-based dietary approaches)
Number of subjects: 0
Study 24269507 — intervention group
Group type: COMPARATOR
Intervention: mPOD (standard reduced calorie dietary approach)
Number of subjects: 0
Study 24269507 — intervention group
Group type: COMPARATOR
Intervention: mPOD
Number of subjects: 0
Study 24269507 — intervention group
Group type: EXPERIMENTAL
Intervention: New DIETs
Number of subjects: 0
Study 22987877 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid human milk fortifier (LHMF)
Number of subjects: 150
Study 22987877 — intervention group
Group type: COMPARATOR
Intervention: Control powder human milk fortifier (HMF)
Number of subjects: 150
Study 20375190 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg for children aged 2-11 months, 20 mg for children aged ≥12 months)
Number of subjects: 2628
Study 18279034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (n = 53)
Number of subjects: 105
Study 18279034 — intervention group
Group type: COMPARATOR
Intervention: Standardized multidimensional care (n = 52)
Number of subjects: 105
Study 16360995 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroid anti-inflammatory (NSAIDs)
Number of subjects: 80